CANTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the date and time of its presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit has been updated.
Continue reading here:
Organogenesis Holdings Inc. Updates Date and Time of Presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
WEST CHESTER, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that positive results from the two pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients [CAMP-1 and CAMP-2]) studies evaluating the safety and efficacy of VP-102 in children and adults with molluscum were published in the Journal of the American Medical Association (JAMA) Dermatology.
See more here:
JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials
RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION
Here is the original post:
RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that a post hoc analysis of the Phase 2 FILLY study investigating intravitreal pegcetacoplan (APL-2) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) has been accepted as a late-breaking oral presentation by EURETINA 2020 Virtual.
BALA CYNWYD, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will virtually present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Monday, September 21, 2020, at 1:40 p.m. EDT.
Original post:
Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two question and answer sessions at the H.C. Wainwright Virtual Precision Oncology Conference on Sept. 24.
View post:
Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference
Simplify Disc overall success rate of 93.0% was superior to the ACDF control Simplify Disc overall success rate of 93.0% was superior to the ACDF control
View original post here:
Simplify Medical Receives FDA Approval for 1-Level Simplify Disc PMA
